COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy and Safety Study of Combination Therapy With Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00733616
Recruitment Status : Completed
First Posted : August 13, 2008
Last Update Posted : February 20, 2013
Hoffmann-La Roche
Information provided by (Responsible Party):
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Brief Summary:
The purpose of the study is to determine efficacy and safety of combination therapy with adjusted-dose docetaxel-oxaliplatin-capecitabine in patients with advanced gastric adenocarcinoma and intermediate general status.(defined as ECOG 2 or weight loss 10-25% or older that 70 years and no comorbidities nor functional dependency nor geriatric syndrome)

Condition or disease Intervention/treatment Phase
Gastric Cancer Drug: DOX: Docetaxel, oxaliplatin, Capecitabine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Adjusted-dose Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status.
Study Start Date : November 2008
Actual Primary Completion Date : May 2012
Actual Study Completion Date : May 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1 Drug: DOX: Docetaxel, oxaliplatin, Capecitabine
  • Docetaxel 40 mg/m2, iv infusion 60 minutes, day 1
  • Oxaliplatin 80 mg/m2, iv infusion 120 minutes, day 1
  • Capecitabine 625 mg/m2, bid, oral, continuous

    6 cycles, every 3 weeks

Capecitabine will be given same dose (625mg/m2/bid) continuous in case no toxicity (no dose adjustment)

Primary Outcome Measures :
  1. objective response rate [ Time Frame: 2008-2011 ]

Secondary Outcome Measures :
  1. adverse events [ Time Frame: 2008-2011 ]
  2. Progression free survival (PFS), time to treatment failure (TTF), overall survival and dose intensity [ Time Frame: 2008-2011 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. informed consent signed
  2. Histological or cytological adenocarcinoma confirmation carcinoma on the esophago-gastric union or stomach (type I, II and III Siervent) metastatic or relapsed
  3. measurable disease (following RECIST criteria)
  4. older or equal 70 years old
  5. Intermediate general status defined as at least one of the following characteristics: performance status (ECOG) = 2, weight loss ponderada between 10 and 25% in the last 3 months
  6. life expectancy superior to 12 weeks
  7. adequate hematological function: Neutrophils ≥1.50x109, platelets ≥100x109, Hemoglobin ≥10 g/dl
  8. adequate liver function: Liver function (total bilirubine < 2 NV; GOT y GPT <3 NV (< 5 NV in case of liver metastasis; Alkaline phosphatase <3 NV ))
  9. Adequate renal function: renal function (Creatinine clearance > 50mL/min), based on Cockroff - Gault. In case Creatinine clearance is < 50 ml/min, a test in urine will be done in 24 hours and if the value is > 50 ml/min, the patient could be eligible for the study
  10. Potential fertile women negative pregnancy test in serum or urine, 10 days prior the first study dose given
  11. Use an adequate contraceptive method (postmenopausal women should be amenorrheic at least 12 months previous the study to be considered as not potentially fertile (VN:upper limit on normal laboratory values)

Exclusion Criteria:

  1. non measurable lesion as only disease evidence
  2. previous chemotherapy treatment for advance disease. It wont´t be consider as exclusion criteria if chemo or radiotherapy has been given for localized disease and finished more than 1 year ago. In caso os only measurable disease in the radiated area, progressive disease has to be documented previous to the inclusion
  3. functional dependency
  4. hypersensitivity to Docetaxel, oxaliplatin or capecitabine
  5. previous serious adverse events or unexpected to fluoropirimidin treatment and /or patients with proved deficit in dehidropirimidin deshidrogenase (DPD)
  6. patients classified as "weak or fragile"

    1. dependency on one or more of the daily activities following the daily activity scale from Katz
    2. three or more comorbitities of the following: congestive cardiac insufficiency, cardiac valvulopathy, coronaripathia, chronic pulmonary disease (obstructive or restrictive), cerebrovascular disease, diabetes, concomitant neoplasms, collagen vascular disease, chronic hetopathy and incapacitate arthritis
    3. presence of geriatric syndromes: moderate-severe dementia, stress delirium (urinary respiratory infection); moderate-severe depression that interfere in the habitual daily life; frequent falls (3 or more monthly); be disattended; urinary incontinence, without stress, infection, diuretics or prostatic hyperplasia; fecal incontinence without diarrhea or laxative; osteoporotic fracture of long bone or vertebral squash
  7. Cardiac concomitant present:

    1. Symptomatic auriculoventricular arrhythmia history, and /or
    2. Congestive cardiac insufficiency non controlled by drugs, and / or
    3. Myocardial infarct 12 months previous the inclusion, and /or
    4. Symptomatic ischemic cardiopathy
  8. active infectious process ((leukocytes superior to 12 x 109/l or fever upper to 38º, it is required thorax X:ray, hemoculture and urine culture 5 days previous to the inclusion)
  9. severe or bad controlled concomitant disease
  10. neoplastic history (except skin basocellular or in-situ cervical carcinoma properly treated) in the last 5 years
  11. patients with any other medical or surgical important problem that, in the investigator opinion, could not allow to follow the treatment
  12. not able to fulfill the protocol and follow-up
  13. being involve in any investigational trial with any drug within 4 weeks prior the study treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00733616

Layout table for location information
Spanish Cooperative Group for Gastrointestinal Tumour Therapy
Madrid, Spain
Sponsors and Collaborators
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Hoffmann-La Roche
Layout table for investigator information
Study Chair: Fernando Rivera, MD; phD Hospital Marques de Valdecilla. Santander. Spain
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) Identifier: NCT00733616    
Other Study ID Numbers: TTD-08-02
EudraCT Nº: 2008-001825-32
First Posted: August 13, 2008    Key Record Dates
Last Update Posted: February 20, 2013
Last Verified: February 2013
Keywords provided by Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD):
advanced gastric adenocarcinoma
intermediate general status
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic